In addition, small clinical trials showed no beneficial effects of conventional PPARγ ligands in cancer patients [41, 42], supporting the idea that PPARγ agonists should be used as chemopreventive agents other than therapeutic drugs. The gene discussed is PPARG; the disease is cancer.